New blood test could slash unnecessary antibiotics in fragile newborns
NCT ID NCT06058819
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether a set of blood markers can accurately rule out late-onset sepsis in newborns in intensive care. Researchers will enroll 358 babies with signs of infection and compare the markers against a panel of experts. If the markers work well, doctors could avoid giving antibiotics to babies who don't need them, reducing resistance and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blood biomarkers (IL6, IL10, NGAL, PCT, PTX3)
- What this could lead to
- If successful, this could give doctors a reliable way to quickly rule out sepsis in newborns, cutting down on unnecessary antibiotics and their side effects.
- What could go wrong
- This is a validation study, not a treatment trial. The biomarkers may not perform as well in this larger group, and the results may not change practice immediately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL LATE ONSET SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Couple-Enfant - CHU Grenoble Alpes
RECRUITINGGrenoble, 38700, France
-
Neonatal intensive care unit, Hôpital femme-maternité
RECRUITINGNantes, 44300, France
-
neonatal Intensive care unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, France
RECRUITINGBron, 69500, France